Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cholestatic liver diseases]

C Reichel, P J Meier-Abt

    Therapeutische Umschau. Revue Therapeutique
    |February 7, 1998
    PubMed
    Summary
    This summary is machine-generated.

    Cholestatic liver disease impairs bile production, leading to various symptoms and complications. Urosodeoxycholic acid (UDCA) is a primary treatment, improving outcomes for conditions like Primary Biliary Cirrhosis (PBC).

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Comparing owner reported and genetic breed identification reveals high concordance in a large cohort from the Dog Aging Project.

    Scientific reports·2025
    Same author

    [Bilateral simultaneous central retinal vein occlusion in protein S deficiency].

    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2015
    Same author

    Optical magnification devices in tonsillectomy: a prospective randomised clinical study.

    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2014
    Same author

    Cathelicidin LL-37 in bronchoalveolar lavage and epithelial lining fluids from healthy individuals and sarcoidosis patients.

    Journal of biological regulators and homeostatic agents·2014
    Same author

    Inefficient expression of the DNA-binding domain of GAL4 in transgenic plants.

    Plant cell reports·2013
    Same author

    Sonography: the leading diagnostic tool for diseases of the salivary glands.

    Seminars in ultrasound, CT, and MR·2013

    Area of Science:

    • Hepatology
    • Gastroenterology
    • Internal Medicine

    Context:

    • Cholestatic liver disease stems from impaired bile production in hepatocytes and cholangiocytes.
    • It presents clinically as intrahepatic or extrahepatic cholestasis, distinguished by bile duct dilation.
    • Intrahepatic cholestasis is often linked to advanced liver cirrhosis, primary cholangiopathies, and hepatocyte transport defects.

    Purpose:

    • To outline the causes, clinical presentation, and management of cholestatic liver diseases.
    • To highlight the symptomatic treatment and complication prevention strategies.
    • To discuss the role of urosodeoxycholic acid (UDCA) and liver transplantation in managing cholestasis.

    Summary:

    • Cholestatic liver disease involves impaired bile flow, affecting hepatocytes and cholangiocytes.

    Related Experiment Videos

  • Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC) are key cholangiopathies with unknown etiologies.
  • Therapy focuses on symptom relief (fatigue, pruritus, jaundice) and preventing complications like cirrhosis and cholangiocarcinoma.
  • Urosodeoxycholic acid (UDCA) is the first-line treatment, reducing bile acid toxicity and improving transplant-free survival in PBC.
  • Liver transplantation remains the definitive option for advanced cholestatic liver disease.

    • Impact:

    • Provides a comprehensive overview of cholestatic liver disease for clinicians and researchers.
    • Emphasizes the importance of symptomatic management and early intervention.
    • Underscores the therapeutic benefits of UDCA and the role of liver transplantation in severe cases.